A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers

开始日期2026-05-12

申办/合作机构

Vicore Pharma AB

CTIS2025-520702-35-00

/ Completed临床1期

A randomised, open-label, 5-period, cross-over trial to assess the pharmacokinetics and safety of 3 oral solid formulations of buloxibutid (C21) in healthy male and female participants

开始日期2025-05-14

申办/合作机构

Vicore Pharma AB

NCT06588686

/ Active, not recruiting临床2期

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
Trial website: www.aspire-ipf.com

开始日期2024-12-09

申办/合作机构

Vicore Pharma AB

[+1]

100 项与 Buloxibutid 相关的临床结果

登录后查看更多信息

100 项与 Buloxibutid 相关的转化医学

登录后查看更多信息

100 项与 Buloxibutid 相关的专利（医药）

登录后查看更多信息

250

项与 Buloxibutid 相关的文献（医药）

2026-02-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis, and biological evaluation of 2-(benzylthio)-5-(indol-3-yl)-1,3,4-oxadiazole derivatives as tubulin polymerization inhibitors with potential anti-cancer effects

Article

作者: You, Jie ; Xie, Qing ; Shi, Jing-Yi ; Man, Ruo-Jun ; Dai, Hong ; Yang, Bing ; Zhu, Hai-Liang

Thirty new 2-(benzylthio)-5-(indol-3-yl)-1,3,4-oxadiazole derivatives were designed, synthesized, and evaluated as tubulin inhibitors against cancers. Some target compounds showed relatively strong anti-proliferative activity against HepG2, HeLa, MCF-7, and A549 cells. Among them, the top hit, compound C21, yielded an IC₅₀ value of 0.08 μM against HeLa cells, exhibiting lower cytotoxicity compared to 293T cells. Tubulin polymerization inhibition assay indicated that the inhibitory activity of compound C21 (IC₅₀: 1.59 ± 0.66 μM) was stronger than that of Colchicine (IC₅₀: 2.52 ± 0.23 μM). Mechanism studies demonstrated that compound C21 could arrest cell cycle at the G2/M phase and induce tumor cell apoptosis in a dose- and time-dependent manner. The confocal imaging further demonstrated that compound C21 could inhibit tubulin polymerization, similar to Colchicine. Moreover, compound C21 showed excellent in vivo anti-tumor potency in a human cervical cancer xenograft mouse model with an inhibitory rate of 80.51 %, which was better than the CA-4P group (49.22 %) and the lower dose group (69.52 %). Furthermore, the docking simulation visualized the possible binding pattern of compound C21 into tubulin. Finally, the information provided in this study will be helpful for the future development of tubulin-related anti-cancer drugs.

2026-01-02·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis

Review

作者: Young, Olivia N. ; Widdop, Robert E. ; Bourke, Jane E.

INTRODUCTION:

Current standard-of-care for idiopathic pulmonary fibrosis is limited to nintedanib and pirfenidone, which only slow the progressive loss of lung function and have significant adverse effects that are intolerable to many patients. There is therefore a significant unmet need for alternative treatments for this incurable disease.

AREAS COVERED:

This review describes emerging evidence implicating dysregulation of the renin-angiotensin system in IPF pathogenesis, and both pre-clinical and recent clinical data supporting activation of the anti-fibrotic AT₂R as a promising therapeutic strategy. The efficacy of AT₂R agonists across pre-clinical models of both IPF and relevant lung diseases is discussed, with a particular focus on favorable findings with the AT₂R agonist C21 (buloxibutid), leading to its current clinical trials for IPF.

EXPERT OPINION:

Rapid translation of C21 (now named buloxibutid), the first-in-class orally available AT₂R agonist, to early phase clinical trials for IPF have established its safety and disease-modifying potential. Ongoing development of novel, more highly selective AT₂R agonists may deliver the same clinical benefit as C21 with reduced off-target effects. The AT₂R drug class offers great promise as novel therapeutics, potentially extending beyond IPF to other inflammatory and fibrotic lung diseases.

2025-12-01·Alzheimers & Dementia

Somatostatin interneuron inhibition as a strategy to restore excitation‐inhibition balance in Alzheimer's disease

Article

作者: Abdallah, Sarena ; Ndambakuwa, Wadzanai ; Algamal, Moustafa ; Bacskai, Brian J. ; Kastanenka, Ksenia V.

Abstract:

Background:

Alzheimer's disease (AD) is characterized by the accumulation of extracellular amyloid plaques, leading to aberrant neuronal activity and an imbalance between excitatory and inhibitory activity. This disruption contributes to network dysfunction and cognitive impairment in AD patients. Our previous work has demonstrated that excitatory neuron activity is reduced in APP/PS1 mice, while somatostatin (SOM) inhibitory interneuron activity is increased near amyloid plaques under isoflurane anesthesia. Given this imbalance, we hypothesized that inhibiting SOM interneurons could restore excitatory neuron activity and improve memory deficits in AD mouse models. To test this, we employed both acute and chronic chemogenetic approaches to manipulate SOM interneuron activity.

Methods:

We used in vivo calcium imaging in APP and wild‐type (WT) mice to evaluate excitatory neurons after acute chemogenetic inhibition of SOM interneurons. For chronic inhibition, we intravenously delivered AAVPHP.eB encoding chemogenetic receptors to achieve non‐invasive, brain‐wide inhibition of SOM interneurons in APP/PS1 and WT mice. We then administered C21 subcutaneously for 16 days, followed by behavioral assessments. Behavioral tests evaluated locomotion and memory consolidation.

Results:

Calcium imaging confirmed that the excitation‐inhibition (E/I) imbalance persists in awake APP mice, demonstrating increased SOM interneuron activity and decreased excitatory neuron activity, mirroring our findings under anesthesia.Acute chemogenetic inhibition of SOM interneurons successfully enhanced excitatory neuron activity, supporting the hypothesis that reducing SOM interneuron activity can restore E/I balance in APP/PS1 mice. However, chronic inhibition of SOM interneurons failed to restore behavioral deficits in APP/PS1 mice, as no significant differences were observed in locomotor activity, working memory, or fear memory acquisition and recall in APP/PS1 or WT mice.

Conclusion:

While acute inhibition of SOM interneurons can restore excitatory neuron activity, brain‐wide chronic inhibition does not effectively improve memory function in APP/PS1 mice under the current experimental conditions.

项与 Buloxibutid 相关的新闻（医药）

2026-05-07

·BioSpace

Vicore Pharma Elects Peter Guenter to its Board of Directors

Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Peter Guenter has been elected as a new member of the Board of Directors. Peter Guenter brings nearly four decades of leadership experience in the global pharmaceutical industry, including roles as Chief Executive Officer at two major European pharmaceutical companies. Most recently, he served as CEO of Merck Healthcare KGaA, following his tenure as CEO of Almirall from 2017 to 2020, where he led a successful strategic refocus on medical dermatology. Before his time at Almirall, Mr. Guenter spent more than 20 years at Sanofi, where he held numerous senior leadership roles of increasing responsibility. He joined Sanofi's Executive Committee in 2013 as Executive Vice President for Global Commercial Operations. Beyond his executive roles, Mr. Guenter is a board member of Ipsen and an industry advisor to private equity firms. "We are delighted to welcome Peter to the Vicore board," said Hans Schikan, Chairman of the Board of Vicore Pharma. "His exceptional track record leading major pharmaceutical companies at the CEO level, combined with his deep commercial and strategic expertise, makes him an outstanding addition to our board at this exciting and consequential stage of Vicore's development. As we advance buloxibutid toward a topline data readout in mid-2027, Peter's experience in building portfolios and executing late-stage development and commercialization strategies will be invaluable." "Peter's appointment is a strong signal of the quality of the opportunity Vicore represents," said Ahmed Mousa, CEO of Vicore Pharma. "Having led transformational efforts at some of the world's most respected pharmaceutical companies, he brings precisely the perspective and expertise we need as we move closer to this important data readout for buloxibutid in IPF, a disease with substantial unmet need. I look forward to working closely with Peter." "I am excited to join the Vicore board at such a pivotal moment for the company," said Peter Guenter. "Buloxibutid represents a genuinely differentiated approach in IPF, a disease where patients urgently need new treatment options. Vicore has built strong scientific, clinical, and operational foundations, and I look forward to contributing to the board's work as the company pursues its mission of delivering a potentially transformational therapy to patients." For more information, please contact: Megan Richards, VP, IR & Comms, +1 978 269 4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. Attachments Vicore Pharma Elects Peter Guenter to its Board of Directors SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire

2026-04-30

·荒城之舞

呼吸系统研究简报 2026年4月30日

呼吸系统研究简报：2026年4月最新动态与进展信息截止日期：2026年4月30日一、执行摘要（BLUF）过去两周内，呼吸系统领域在预防性单抗、吸入三联维持治疗、COPD/ IPF/CF 管线推进，以及基于痰液的 AI 精准诊断方面均有重要进展。监管层面，默沙东（MSD）的 RSV 预防性单抗 Enflonsia 获得欧盟批准，阿斯利康的 Breztri Aerosphere 获 FDA 批准用于 12 岁及以上哮喘维持治疗，为儿童及成人呼吸疾病管理提供了新的规范治疗选项（具体使用仍需依据当地指南和监管要求）。临床研发方面，阿斯利康 IL‑33 单抗 tozorakimab 在 COPD III 期 MIRANDA 试验中达到主要终点；Nuance Pharma 的 Ohtuvayre（ensifentrine）在中国中重度 COPD 成人患者 ENHANCE‑CHINA III 期研究中显示肺功能改善，并已发表于《CHEST》期刊。 IPF 领域，Vicore Pharma 的 buloxibutid（ASPIRE IIb 期试验）完成超过 360 例入组，预计于 2027 年年中公布顶线结果；Rein Therapeutics 的吸入制剂 LTI‑03 在 II 期 RENEW 试验中已完成早期患者入组，研究仍在扩展中。囊性纤维化及诊断创新方面，Sionna Therapeutics 宣布 NBD1 稳定剂 SION‑719 联合 Trikafta 的 PreciSION CF IIa 期试验完成入组，预计 2026 年夏季公布初步结果；bioAffinity Technologies 与 Brooke Army Medical Center 启动基于痰液流式细胞术与 AI 分析的试点研究，探索哮喘和 COPD 生物标志物检测的可行性，为未来的精准诊断工具开发奠定基础。注：以下所有内容仅为研发与监管信息情报整理，不构成任何治疗建议或推广性陈述。具体用药与治疗决策应依据各国/地区批准适应症、临床指南及医师判断。二、监管批准与市场准入动态 2.1 Enflonsia（clesrovimab）获欧盟批准用于婴幼儿 RSV 预防关键信息 2026年4月，欧洲委员会批准默沙东（MSD/Merck）的 Enflonsia（通用名 clesrovimab），用于预防新生儿及婴儿在首个 RSV 流行季期间由呼吸道合胞病毒引起的下呼吸道疾病。该批准覆盖所有欧盟成员国以及冰岛、列支敦士登和挪威，为该人群提供了额外的被动免疫预防选择。 Enflonsia 为长效单克隆抗体，设计为单次给药覆盖约一个 RSV 流行季，批准基于多项 IIb/III 期临床试验结果（如 CLEVER、SMART 试验），显示在预防 RSV 相关下呼吸道疾病方面达到了预设终点。风险与不确定性提示当前数据主要来自受控临床试验，真实世界人群中的有效性、安全性、成本效益和与现有疫苗/单抗策略的协同关系仍需进一步观察。各成员国是否将其纳入免疫规划、报销及具体使用方案，将受制于卫生技术评估（HTA）及预算影响分析等因素。推荐参考来源 MSD 官方新闻稿（2026-04）。 Pharmaceutical Technology 等行业媒体对 Enflonsia 批准的综述报道。 2.2 Breztri Aerosphere 获 FDA 批准用于 12 岁及以上哮喘维持治疗关键信息 2026年4月，阿斯利康宣布 Breztri Aerosphere 获 FDA 批准，用于成人及 12 岁及以上青少年哮喘患者的维持治疗，为美国首个获批的单吸入器 ICS/LABA/LAMA 三联维持治疗方案。 Breztri 含布地奈德（ICS）、格隆溴铵（LAMA）和富马酸福莫特罗（LABA），此前已在 COPD 适应症获批，此次为标签扩展至哮喘人群。批准主要基于 KALOS 和 LOGOS 两项 III 期试验结果，这些研究显示，在中重度哮喘患者中，Breztri 相较 ICS/LABA 双联方案在肺功能和部分临床终点方面有改善趋势。风险与不确定性提示 FDA 批准并不意味着该方案适用于所有哮喘患者，具体使用人群和治疗路径仍需结合专业指南更新及保险/支付方政策。尚需更多真实世界研究以评估其长期安全性、急性发作控制、依从性及与其他吸入方案的相对价值。推荐参考来源 AstraZeneca 递交给 SEC 的 6-K 报告及公司新闻稿。《Pharmaceutical Executive》等媒体对 Breztri 哮喘适应症批准的解读。三、慢性阻塞性肺疾病（COPD）研发进展 3.1 IL‑33 单抗 tozorakimab：MIRANDA III 期试验达主要终点关键信息阿斯利康开发的 IL‑33 单抗 tozorakimab 在 COPD 患者中开展的 MIRANDA III 期随机对照试验近期公布结果，显示在既往吸烟者人群以及整体入组人群中，均显著降低了中重度急性加重的年化发生率（相较安慰剂）。该试验为大型多中心研究，是 tozorakimab COPD 开发项目的一部分，公司同时提及 OBERON 与 TITANIA 等其他 III 期试验结果也将支持后续注册策略。风险与不确定性提示目前公开信息来自公司新闻稿与行业媒体报道，详细临床数据（如绝对风险差、不同亚组表现、安全性概况等）尚未在同行评议期刊中完整发表。 IL‑33 通路阻断在 COPD 中的长期获益-风险比、与现有吸入治疗和生物制剂的序贯/联合策略仍在探索阶段。推荐参考来源 Clinical Trials Arena 对 tozorakimab III 期结果的报道。市场分析文章（如 MarketChameleon 对 IL‑33 抗体在 COPD 中定位的解读）。 3.2 Ohtuvayre（ensifentrine）ENHANCE‑CHINA III 期结果发表于《CHEST》关键信息 Nuance Pharma 宣布，Ohtuvayre（通用名 ensifentrine，一种双重 PDE3/4 抑制剂）在中国中重度 COPD 成人患者开展的 ENHANCE‑CHINA III 期研究结果，已发表于《CHEST》期刊。研究纳入约 526 名中国成人受试者，试验结果显示，与对照组相比，Ohtuvayre 在肺功能指标方面（如 FEV1 变化）表现出统计学改善，并具有总体可接受的安全性特征。风险与不确定性提示虽然公司新闻稿提及“肺功能改善”，但对呼吸困难评分、急性加重率及生活质量等二级终点的具体效应大小和临床意义仍需结合原始论文数据详细解读。适应症获批情况及在中国的具体定价、报销及临床采用需要关注后续 NMPA 及医保谈判动态。推荐参考来源 Nuance Pharma 官方新闻稿及其引用的《CHEST》原文。四、特发性肺纤维化（IPF）临床管线进展 4.1 buloxibutid（Vicore Pharma）：ASPIRE IIb 期试验完成入组关键信息 Vicore Pharma 宣布，其 ATRAG 小分子 buloxibutid 在 IPF 患者中的 ASPIRE IIb 期随机、安慰剂对照试验已完成入组，超过 360 例患者来自 14 个国家、100 余家中心。 ASPIRE 试验主要评估 52 周内 FVC 变化及其他肺功能和临床终点，公司预计将于 2027 年年中公布顶线结果。风险与不确定性提示作为 IIb 期探索性试验，ASPIRE 的阳性结果将为后续 III 期确证性研究提供基础，但不能直接推断为即将获批或将成为标准治疗。 buloxibutid 作用机制相对新颖，长期安全性、合并用药策略及与现有抗纤维化药物联用的可行性需进一步研究。推荐参考来源 Vicore Pharma 投资者新闻稿（2026-04）及 NASDAQ 公告页面。 4.2 LTI‑03（Rein Therapeutics）：RENEW II 期试验早期入组进展关键信息 Rein Therapeutics 开展的吸入干粉制剂 LTI‑03 在 IPF 患者中的 RENEW II 期试验为多国多中心、随机、双盲、安慰剂对照研究，计划入组约 120 名患者。截至 2026 年 4 月下旬，公司披露该试验已入组 8 名患者，另有 2 名患者预计近期入组，中心目前位于美国、澳大利亚和波兰，并计划向英国和德国扩展。风险与不确定性提示 RENEW 仍处于早期入组阶段，短期内难以获得关键疗效与安全性结论，后续患者招募速度和全球站点开放情况将影响数据读出时间。公司尚未更新新的顶线结果时间表，内部预测类内容应谨慎引用，避免对时间节点作过度承诺。推荐参考来源 Rein Therapeutics 关于 RENEW 试验启动与进展的多轮新闻稿。五、囊性纤维化（CF）与精准诊断创新 5.1 SION‑719 + Trikafta 联用：PreciSION CF IIa 期完成入组关键信息 Sionna Therapeutics 宣布，NBD1 稳定剂 SION‑719 联合 Trikafta 的 PreciSION CF IIa 期临床试验已完成入组，该试验在成年 F508del 突变纯合囊性纤维化患者中评估短期安全性、药代及关键生物标志物变化。该试验为随机、双盲、安慰剂对照、交叉设计的 proof‑of‑concept 研究，公司预计于 2026 年夏季公布初步结果，用于评估 NBD1 稳定剂在现有 CFTR 调节剂基础上的增益潜力。风险与不确定性提示当前为 IIa 概念验证阶段，样本量有限且随访时间较短，尚不足以支撑对长期临床结局（如肺功能下降速度、急性加重、住院率等）的判断。若初步结果积极，仍需更大规模 IIb/III 期试验验证其在不同基因型及疾病阶段患者中的适用性。推荐参考来源 Sionna Therapeutics 官方新闻稿及二级媒体报道。 5.2 痰液流式细胞术 + AI：bioAffinity–BAMC 试点研究关键信息 bioAffinity Technologies 与 Brooke Army Medical Center（BAMC）合作启动一项试点研究，拟招募约 40 名受试者，涵盖哮喘患者、COPD 患者及健康对照人群。研究基于公司 CyPath Lung 平台，通过痰液流式细胞术分析免疫细胞亚群和相关生物标志物，并引入人工智能算法进行模式识别，以探索呼吸道炎症表型分型和潜在诊断/监测工具的可行性。风险与不确定性提示目前为单中心/多中心规模较小的探索性研究，主要用途在于方法学验证和特征发现，不宜视为临床实践可直接采纳的诊断方案。痰液样本质量、前处理标准化、算法可解释性及跨平台可重复性均是未来转化为临床工具前需要重点解决的问题。推荐参考来源 bioAffinity Technologies 官方新闻稿（2026-04-27）。六、附录：信息使用与合规提示本简报基于公开渠道（企业新闻稿、监管机构公告、主流医学/行业媒体报道及部分已发表期刊文章）进行梳理与整合，信息截至 2026 年4月30日，如无特别说明，暂未包含未公开或会议口头报告数据。所有研发进展均为临床研究或监管动态信息，不代表任何药物在中国或其他市场的上市状态、可及性或报销情况。任何适应症、剂量和用法用量等内容应以各国/地区官方批准说明书及当地法规为准。文中如使用“显示改善”“达到主要终点”“提示潜在价值”等用语，均对应特定临床试验预设终点及统计学分析结果，临床意义和推广价值仍需结合后续指南更新、真实世界研究及卫生技术评估综合判断。

2026-04-29

·BioSpace

Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference

STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present multiple posters at the 2026 American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida from May 15 - May 20, 2026. The abstracts include analyses from the completed Phase 2a AIR trial in idiopathic pulmonary fibrosis (IPF), as well as translational research exploring the biological pathways associated with angiotensin II type 2 (AT2) receptor activation. Buloxibutid's Efficacy in the Phase 2a AIR IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts This analysis evaluates baseline clinical and imaging characteristics of patients included in the Phase 2a AIR trial, comparing patients recruited in India with an external global IPF dataset. The analysis explores demographic, physiological, and high-resolution CT-derived imaging features to assess comparability across regions. Poster Discussion Session C103: The Next Frontier of Therapy in Pulmonary Fibrosis Date: Tuesday, May 19, 2026 Time: 2:15 PM ET Location: West F3 (Level II, OCCC West Concourse) Buloxibutid Stabilizes and Improves Lung Function in Idiopathic Pulmonary Fibrosis and Elevates Plasma MMP-13, Linking AT2 Receptor Activation in Alveolar Epithelial Type 2 Cells to Resolution of Fibrosis This poster integrates findings from the 36‑week Phase 2a AIR trial with mechanistic preclinical analyses to explore biological pathways associated with AT2 receptor activation. The work examines changes in plasma matrix metalloproteinase‑13 (MMP‑13) in patients with IPF treated with buloxibutid, alongside cellular expression patterns in lung tissue from healthy and bleomycin‑treated rats elucidating the role of the AT2 receptor activation in epithelial cell-related processes in pulmonary fibrosis. Poster Discussion Session A110: Closing the Gap: Advances in Pulmonary Fibrosis Date: Sunday, May 17, 2026 Time: 2:15 PM ET Location: West F3 (Level II, OCCC West Concourse) Microvascular Normalization and Fibrosis Regression by the Angiotensin II Type 2 Receptor Agonist Buloxibutid in Pulmonary Hypertension Associated with Interstitial Lung Disease This poster presents preclinical research evaluating the effects of buloxibutid in the Sugen‑Hypoxia (SuHx) rat model, which is relevant to pulmonary hypertension and fibrotic lung disease. The study examines changes in pulmonary blood vessels and lung fibrosis following treatment with buloxibutid to examine the potential of AT2 receptor agonism in both pulmonary hypertension and IPF. Poster Discussion Session D109: Novel Insights into Pulmonary Vascular Diseases Date: Wednesday, May 20, 2026 Time: 11:00 AM ET Location: W414AB (Level IV, OCCC West Concourse) Following the presentations, each poster will be available on the Publications page of Vicore's website at In addition, Vicore has been selected to present at the ATS 2026 Respiratory Innovation Summit, a meeting attracting representatives from pharma business development, venture capital, government, academia, and clinical medicine, on May 16, 2026. For more information, please contact: Megan Richards, VP, IR & Comms, +1 978 269 4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. Attachments Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire

临床2期快速通道孤儿药

100 项与 Buloxibutid 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	美国	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	阿根廷	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	巴西	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	哥伦比亚	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	捷克	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	印度	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	菲律宾	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	俄罗斯	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	南非	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	乌克兰	Vicore Pharma AB	2021-09-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04533022 (AIR, CTgov)	临床2期	特发性肺纤维化	52	C21 (C21 100 mg BID, SAS)	窪願顧網遞齋製衊夢鹹 = 網鏇醖鬱蓋構夢鬱壓網網繭夢鏇顧艱築獵糧壓 (衊鏇鹹鹽齋糧獵鹹範繭, 範壓範願構鹹鏇鬱鹹鑰 ~ 構膚襯顧壓獵襯醖築醖) 更多	-	2025-05-23
				C21 (C21 100 mg BID)	齋鹽壓淵窪築顧願齋範(願鑰廠衊構廠簾齋製衊) = 網鏇襯範齋遞鑰齋膚憲獵顧淵夢蓋窪鏇願鹽艱 (窪願選網構繭鑰醖壓選, 憲壓廠膚製製膚鑰獵獵 ~ 繭蓋築糧鹽餘艱範餘製) 更多
NCT05277922 (CTgov)	临床1期	-	5	C21 (C21 3 ug/Min)	積繭願憲鹹選蓋齋壓範(製襯齋襯獵鏇顧蓋遞蓋) = 衊選選鬱製蓋網壓醖築鏇願夢鑰襯積齋範艱製 (憲壓窪簾築醖願廠製觸, 24.3) 更多	-	2025-04-23
				C21 (C21 10 ug/Min)	積繭願憲鹹選蓋齋壓範(製襯齋襯獵鏇顧蓋遞蓋) = 鹽鹽鹽獵獵蓋選網願遞鏇願夢鑰襯積齋範艱製 (憲壓窪簾築醖願廠製觸, 5.5) 更多
NCT05831644 (CTgov)	临床1期	2型糖尿病 \| 内皮功能障碍	11	C21 (C21 Treatment)	糧憲餘餘廠餘夢憲繭顧(選範築鬱顧餘鹽餘夢顧) = 衊鹹獵網鑰膚構襯鏇齋選範獵醖衊簾製鹽廠鬱 (齋繭醖鬱糧廠齋艱製衊, 0.062) 更多	-	2024-11-12
				placebo (Placebo Treatment)	糧憲餘餘廠餘夢憲繭顧(選範築鬱顧餘鹽餘夢顧) = 網願艱齋糧窪簾膚壓遞選範獵醖衊簾製鹽廠鬱 (齋繭醖鬱糧廠齋艱製衊, 0.062) 更多
NCT04533022 (AIR, ATS2024) 人工标引	临床2期	特发性肺纤维化	46	Buloxibutid	鹹築積糧鏇襯蓋衊築鑰(醖壓鹽艱製獵蓋繭鹹遞) = 餘夢餘夢範鹽顧觸觸鹹窪夢艱齋網鹹艱廠構艱 (膚醖餘壓遞餘顧鹽艱淵, -150 ~ +50) 更多	积极	2024-04-29
NCT04880642 (ATTRACT-3, CTgov)	临床3期	新型冠状病毒感染	272	C21 (C21 Treatment)	範鬱選艱襯衊夢觸夢積 = 齋製築鑰淵繭遞觸鑰繭夢醖顧衊選構遞觸顧繭 (餘膚鬱鹽窪鹽艱簾積獵, 壓選鏇繭構憲鏇願鏇觸 ~ 淵艱襯齋淵憲夢壓廠糧) 更多	-	2023-12-14
				placebo (Placebo Treatment)	範鬱選艱襯衊夢觸夢積 = 積鹹鹹繭繭蓋範壓齋積夢醖顧衊選構遞觸顧繭 (餘膚鬱鹽窪鹽艱簾積獵, 鬱醖醖鏇鹹齋鑰齋範糧 ~ 範鹹蓋鏇積蓋餘鏇獵齋) 更多
ATS2023	N/A	特发性肺纤维化	-	C21 100 mg twice daily	窪鹽壓艱膚衊窪繭夢範(餘網構範蓋遞觸鏇鬱顧) = 3 SAE's none of which were treatment related inclusive of 1 death (COVID-19) 壓淵夢襯醖襯遞鑰積糧 (齋餘糧壓簾夢製積齋餘 ) 更多	-	2023-05-21
NCT04388176 (CTgov)	临床2期	雷诺病 \| 系统性硬皮病	20	placebo (Placebo)	遞網膚觸齋衊淵範鹹網(獵糧繭鏇範醖構遞願艱) = 鑰鹹選窪艱鹽憲醖壓壓鏇願蓋醖獵夢衊選遞顧 (顧鹹積齋憲艱網膚鹹顧, 4.36) 更多	-	2023-05-18
				C21 (C21 200 mg)	遞網膚觸齋衊淵範鹹網(獵糧繭鏇範醖構遞願艱) = 網壓糧繭餘鹹選築顧鹽鏇願蓋醖獵夢衊選遞顧 (顧鹹積齋憲艱網膚鹹顧, 7.68) 更多
NCT04533022 (AIR, Corporate Publications) 人工标引	临床2期	特发性肺纤维化	45	C21	淵願廠願構鏇膚選選鏇(鏇餘襯襯糧餘鹹觸窪繭) = 積鑰構夢齋鑰積衊壓網壓遞選膚膚蓋鏇襯簾積 (淵蓋襯觸鏇憲觸齋艱鏇 ) 更多	积极	2022-11-05
NCT04533022 (AIR, ERS2022)	临床2期	特发性肺纤维化	21	C21 100 mg	築築壓鑰鏇夢窪選蓋糧(選選獵範糧遞壓積窪夢) = no signals of gastro-intestinal toxicity 鏇窪範艱築廠獵齋築膚 (鏇築餘淵鹽製夢簾襯顧 ) 更多	积极	2022-09-04
NCT04452435 (ATTRACT, ESC2022)	临床2期	新型冠状病毒感染 NT-proBNP	206	C21	憲築願艱襯鏇醖鹽積製(築鑰鬱齋艱餘醖鹹築餘) = 憲鹹蓋壓積網選顧簾窪齋襯鑰夢艱築憲廠鹹壓 (觸鹽繭願餘鹽願網壓夢 )	-	2022-08-29
				Placebo	憲築願艱襯鏇醖鹽積製(築鑰鬱齋艱餘醖鹹築餘) = 範淵襯衊餘餘鹹憲衊憲齋襯鑰夢艱築憲廠鹹壓 (觸鹽繭願餘鹽願網壓夢 )